Does Horizon Blue Cross Blue Shield of New Jersey Cover Dupixent?

What Is Dupixent and Why Does Coverage Matter?

Dupixent (dupilumab) is a fully human monoclonal antibody that blocks the shared receptor component for interleukin-4 (IL-4) and interleukin-13 (IL-13), two cytokines central to type-2 inflammatory disease. The FDA first approved dupilumab in March 2017 for adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical therapies. 1

Since that initial approval, the FDA has expanded dupilumab's label to cover add-on maintenance therapy for moderate-to-severe asthma with an eosinophilic phenotype, chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis in patients aged 12 and older, prurigo nodularis in adults, and, as of 2024, moderate-to-severe COPD with an eosinophilic phenotype. Each new indication carries its own coverage criteria under insurance plans. 2

Why the List Price Creates Urgency

Dupixent's wholesale acquisition cost exceeds $40,000 per year, making insurance coverage decisions financially consequential for patients. 3 Without coverage or manufacturer assistance, few patients can sustain therapy. That financial reality is why understanding exactly how Horizon BCBSNJ evaluates dupilumab claims matters before the first injection is given.

IL-4/IL-13 Blockade: The Clinical Rationale

The SOLO-1 and SOLO-2 trials (combined N=1,379) demonstrated that dupilumab 300 mg every two weeks produced an Investigator Global Assessment (IGA) score of 0 or 1 in 36 to 38% of patients at 16 weeks, compared with 8 to 10% for placebo (P<0.001). 4 Those results established the clinical standard that Horizon BCBSNJ's medical policies reference when defining "adequate response" for step-therapy purposes.

How Horizon BCBSNJ Structures Its Formulary for Specialty Drugs

Horizon Blue Cross Blue Shield of New Jersey operates multiple plan types: commercial PPO and HMO products, Medicare Advantage plans (branded Horizon Advantage), Medicaid Managed Care under NJ FamilyCare (Horizon NJ Health), and employer self-funded plans subject to administrative services agreements. Dupilumab's coverage rules differ by product line.

Commercial Plan Formulary Placement

On Horizon BCBSNJ commercial plans, dupilumab is typically placed on Specialty Tier 4 or Tier 5. Specialty tiers use coinsurance (commonly 20 to 30% of the negotiated cost) rather than flat copays, which means out-of-pocket exposure per injection can reach several hundred dollars even after meeting the deductible.

The American Academy of Dermatology guidelines note that specialty-tier cost-sharing structures "may create significant barriers to access for biologic therapies that have demonstrated clear superiority over conventional treatments." 5 Horizon's formulary design is consistent with most large commercial insurers in the Mid-Atlantic region.

Medicare Advantage and Part D Rules

Horizon's Medicare Advantage plans (Horizon Advantage) cover dupilumab under Part B or Part D depending on the clinical setting. When a physician administers dupilumab in an office or infusion center, Part B applies. Self-administered at-home injections fall under Part D specialty tiers.

Medicare Part D specialty tiers carry a standard cost-sharing of 25 to 33% after the deductible, but the Inflation Reduction Act of 2022 capped Medicare beneficiary out-of-pocket drug costs at $2,000 annually beginning in 2025. 6 That cap meaningfully changes the cost calculus for Horizon Advantage members using dupilumab.

NJ FamilyCare / Medicaid Coverage

New Jersey's Medicaid program (NJ FamilyCare), administered in part by Horizon NJ Health, covers dupilumab for atopic dermatitis following the state's preferred drug list criteria. Approval generally requires documented moderate-to-severe disease severity (an Eczema Area and Severity Index score of ≥16 or EASI ≥21 in clinical practice), failure of at least one high-potency topical corticosteroid, and in some cases failure of a systemic agent such as cyclosporine. 7

Prior Authorization Criteria for Dupixent on Horizon BCBSNJ Plans

Prior authorization (PA) is required for dupilumab on virtually every Horizon BCBSNJ product. The PA process exists to confirm clinical appropriateness before the plan commits to coverage. Missing a single documentation element is the most common reason for initial denial.

Atopic Dermatitis PA Requirements

For atopic dermatitis, Horizon BCBSNJ PA criteria typically require all of the following:

• Confirmed diagnosis of moderate-to-severe atopic dermatitis by a board-certified dermatologist or allergist
• EASI score ≥16 or BSA involvement ≥10% documented in the medical record within the prior 6 months
• Documented trial and failure (inadequate response or intolerance) of at least one medium-to-high-potency topical corticosteroid for a minimum of 4 continuous weeks
• Prescription written by or in consultation with a specialist (dermatologist, allergist, or immunologist)
• Patient age at or above the FDA-approved minimum (6 months for atopic dermatitis as of the 2023 label update)

Asthma PA Requirements

For add-on maintenance therapy in asthma, Horizon BCBSNJ typically requires:

• Confirmed diagnosis of moderate-to-severe asthma
• Blood eosinophil count ≥150 cells/mcL at screening or ≥300 cells/mcL in the past 12 months, OR elevated fractional exhaled nitric oxide (FeNO ≥25 ppb)
• Documented use of an inhaled corticosteroid at medium-to-high dose for at least 3 months
• Prescription from a pulmonologist or allergist

The LIBERTY ASTHMA QUEST trial (N=1,902) found dupilumab 200 mg or 300 mg every two weeks reduced severe exacerbations by 47.7% relative to placebo in patients with baseline eosinophils ≥300 cells/mcL (P<0.001). 8 Horizon's medical policy documents cite this threshold when defining the eosinophil criterion.

CRSwNP and Other Indications

For chronic rhinosinusitis with nasal polyposis, Horizon BCBSNJ typically requires prior bilateral polypectomy or documented surgical candidacy, ongoing systemic corticosteroid use, and nasal endoscopy confirming bilateral polyps. The SINUS-24 and SINUS-52 trials demonstrated that dupilumab reduced nasal polyp scores by 51% at 52 weeks compared with placebo. 9

Step Therapy: What You Must Try First

Step therapy (also called "fail first") requires patients to try less expensive drugs before the plan will approve dupilumab. New Jersey enacted the Step Therapy Reform Act (N.J. Stat. Ann. §17B:27-46.1i) to limit but not eliminate step therapy requirements for commercial plans. 10

What Step Therapy Typically Looks Like for Atopic Dermatitis

Most Horizon BCBSNJ commercial plans require documented failure of:

1. A medium-to-high-potency topical corticosteroid (e.g., triamcinolone 0.1%, clobetasol 0.05%) for at least 4 weeks
2. In some plan designs, a topical calcineurin inhibitor (tacrolimus 0.1% ointment) for at least 4 weeks

Step therapy does not generally require failure of systemic immunosuppressants (cyclosporine, methotrexate) on most Horizon commercial plans, which aligns with AAD-AAAAI joint guidelines published in 2023. 11

New Jersey's Step Therapy Protections

Under N.J. Stat. Ann. §17B:27-46.1i, a commercial insurer must grant a step therapy exception when:

• The required drug is contraindicated or likely to cause an adverse reaction
• The patient previously failed the required drug
• The required drug is not clinically appropriate for the patient's condition

These exemptions give prescribers a concrete legal pathway to bypass step therapy when medical records document prior failure. Provide the insurer with office notes, pharmacy records showing dispensing dates, and a letter of medical necessity that quotes the specific statutory language.

How to Submit a Prior Authorization That Gets Approved

Incomplete documentation is responsible for the majority of initial PA denials. Building the submission correctly the first time is more efficient than appealing a denial.

Required Documentation Checklist

• Office note from a specialist (dermatologist, allergist, or pulmonologist) dated within 6 months
• Documented severity score (IGA, EASI, or SCORAD for atopic dermatitis; ACQ-5 for asthma; SNOT-22 for CRSwNP)
• Pharmacy records or office notes confirming step therapy completion with dates and doses
• Letter of medical necessity on practice letterhead citing the FDA indication and the relevant clinical trial data
• Current medication list confirming the patient is not on a contraindicated concurrent therapy

Common Reasons Horizon BCBSNJ Denies Dupixent PAs

Horizon denies dupilumab PAs most often for the following reasons (in order of frequency):

1. Step therapy not completed or documentation missing dates
2. Severity criteria not met (no documented severity score in the chart)
3. Diagnosis code mismatch (e.g., using L20.9 for atopic dermatitis without documentation of "moderate-to-severe" severity in the note body)
4. Prescriber not recognized as a specialist for the indication

Fix each of these before submitting, not during the appeal.

Appealing a Denial: The Four-Level Process

A denied PA is not the end of the road. Horizon BCBSNJ, like all New Jersey commercial insurers, must comply with the New Jersey Independent Health Care Appeals Program (IHCAP) administered by the New Jersey Department of Banking and Insurance. 12

Level 1: Internal Appeal

File within 180 days of the denial notice. Submit all documentation listed above plus a peer-reviewed article (SOLO-1/SOLO-2, LIBERTY ASTHMA QUEST, or the relevant key trial) demonstrating clinical superiority over the required step-therapy agent for the patient's specific phenotype.

Level 2: Peer-to-Peer Review

Request a peer-to-peer call between the prescribing specialist and Horizon's medical director. This step alone reverses denials in a substantial proportion of cases according to published data on biologic appeals. Schedule this call within 5 business days of the denial to maintain momentum.

Level 3: External Independent Review (IHCAP)

If the internal appeal fails, request external review through IHCAP within 60 days of the internal appeal denial. New Jersey law requires Horizon to comply with the external reviewer's decision. The external reviewer is a board-certified clinician in the relevant specialty who has no financial relationship with Horizon BCBSNJ.

Level 4: State Insurance Commissioner Complaint

File a formal complaint with the New Jersey Department of Banking and Insurance if IHCAP finds in Horizon's favor but you believe the plan violated state law. This step is uncommon but available.

Dupixent Patient Assistance Programs That Reduce Cost During the Appeal

While the PA or appeal is pending, patients may access dupilumab at reduced cost through two programs.

Sanofi/Regeneron DUPIXENT MyWay Copay Card

Commercially insured patients who are not enrolled in a government-funded health plan (Medicare, Medicaid, CHIP, TRICARE) may qualify for the DUPIXENT MyWay copay card. Eligible patients may pay as little as $0 per fill for the first year and no more than $35 per fill thereafter, subject to program terms. 13

The copay card does not apply to Medicare or Medicaid beneficiaries, because federal anti-kickback statutes prohibit manufacturer copay assistance for government-program patients.

Sanofi Patient Assistance Program (PAP)

Patients without insurance or whose insurance denies coverage may qualify for free Dupixent through Sanofi's PAP if household income is at or below 600% of the federal poverty level. Applications are processed through DUPIXENT MyWay at 1-844-DUPIXENT.

NeedyMeds and State Pharmaceutical Assistance

New Jersey does not operate a state pharmaceutical assistance program specifically for dupilumab, but NeedyMeds.org aggregates additional assistance options by drug and zip code. 14

Real-World Effectiveness Data Supporting Coverage

Payers increasingly weigh real-world evidence alongside randomized trial data when setting formulary policy.

PROSE Registry Findings

The PROSE registry, a prospective U.S. Real-world study of dupilumab in atopic dermatitis (N=304 adults), found a mean EASI reduction of 68% at 6 months in patients with baseline EASI ≥16. 15 That real-world magnitude of effect matches key trial outcomes, which strengthens the medical necessity argument in appeals.

Quality-of-Life Burden

A 2022 analysis in JAMA Dermatology reported that moderate-to-severe atopic dermatitis carries a quality-adjusted life-year (QALY) burden comparable to moderate heart failure. 16 Cost-effectiveness models place dupilumab's incremental cost-effectiveness ratio at approximately $65,000, $80,000 per QALY gained in moderate-to-severe disease, within the commonly cited $100,000/QALY willingness-to-pay threshold used by the Institute for Clinical and Economic Review (ICER). 17

The HealthRX Prior Authorization Decision Framework for Dupixent on Horizon BCBSNJ plans (see editorial figure) maps the PA submission pathway, the appeal levels, and the patient assistance eligibility branch points into a single clinical workflow. The framework is designed for use by dermatology and allergy practice managers submitting PAs on behalf of New Jersey patients.

Pediatric Coverage Considerations

The FDA approved dupilumab for atopic dermatitis in children as young as 6 months in May 2023. 18 Horizon BCBSNJ commercial plans and Horizon NJ Health (Medicaid) generally follow the FDA label for minimum age, but pediatric PAs face an additional layer of scrutiny.

Dosing in Children

Pediatric dosing is weight-based for patients under 60 kg. Children 6 months to 5 years weighing 5 to <15 kg receive 200 mg every 4 weeks; 15 to <30 kg receive 300 mg every 4 weeks; and patients 30 to <60 kg receive 400 mg every 4 weeks or 200 mg every 2 weeks. These dose tiers must be specified correctly on the PA form, because an incorrect dose may trigger a formulary rejection on technical grounds.

Pediatric Step Therapy

Pediatric step therapy for atopic dermatitis on Horizon plans typically requires failure of low-to-medium-potency topical corticosteroids (not high-potency agents, which are avoided in children under 2 years) for at least 4 weeks. Tacrolimus 0.03% ointment (the pediatric formulation) may be required as an additional step in some plan designs.

Biosimilar Competition and Future Coverage Shifts

The first dupilumab biosimilars are in clinical development, with regulatory submissions anticipated in 2026 to 2027 following patent expiry litigation. 19 When biosimilars reach market, Horizon BCBSNJ may introduce preferential biosimilar coverage, requiring patients on originator dupilumab to non-medical switch unless they qualify for a continuity-of-care exemption.

Prescribers should document current IGA or EASI scores annually so that any future non-medical switch request can be contested with objective efficacy data showing disease control on the originator product.

Key Contacts and Resources for Horizon BCBSNJ Dupixent Coverage

• Horizon BCBSNJ pharmacy PA line: 1-800-365-2223 (commercial plans)
• Horizon BCBSNJ Medicare Advantage member services: 1-800-355-2583
• DUPIXENT MyWay: 1-844-387-4936 or dupixent.com/support-and-savings
• New Jersey IHCAP (external appeals): njconsumeraffairs.gov or 1-800-446-7467
• NJ Department of Banking and Insurance (insurance complaints): 1-800-446-7467